THE TRAVEL II TRIAL: Transcatheter Right Atrial-ventricular Valve rEplacement With LuX-Valve Via Jugular Vein

NARecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Tricuspid Valve Regurgitation
Interventions
DEVICE

Tricuspid Valve Replacement System via jugular vein

To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system via jugular vein.

Trial Locations (9)

100029

NOT_YET_RECRUITING

Beijing Anzhen Hospital, Beijing

100037

NOT_YET_RECRUITING

Fu Wai Hospital, Beijing

200433

RECRUITING

Changhai Hospital, Shanghai

310000

NOT_YET_RECRUITING

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

430000

NOT_YET_RECRUITING

Wuhan Union Hospital, Wuhan

510000

NOT_YET_RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

610000

NOT_YET_RECRUITING

West China Hospital, Chengdu

710000

NOT_YET_RECRUITING

Xijing Hospital, Xi'an

Unknown

RECRUITING

Shanghai Zhongshan Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Zhongshan Hospital

OTHER

collaborator

Fu Wai Hospital, Beijing, China

OTHER

collaborator

Beijing Anzhen Hospital

OTHER

collaborator

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

collaborator

West China Hospital

OTHER

collaborator

Xijing Hospital

OTHER

collaborator

Guangdong Provincial People's Hospital

OTHER

collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

lead

Changhai Hospital

OTHER